Effectiveness of VR Rehabilitation for People With Asymmetrical Gait Patterns

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-65
SponsorUniversity of Rzeszow

About this trial

A randomized comparative study will be conducted to evaluate the rehabilitation process using a VR-based application versus conventional therapy in 40 patients (sample size determined using a sample size calculator). After meeting the eligibility criteria, participants will be randomly assigned to two groups: the experimental group (20 patients with gait pattern asymmetry), performing a gait training program using a VR rehabilitation application, and the control group (20 patients with gait pattern asymmetry), performing only a conventional gait training program.

Participants in both groups will take part in a 2-week rehabilitation program (Monday to Friday), with daily training sessions lasting up to 2 hours. Patient assessment will be conducted twice: an initial evaluation before the start of the intervention (Assessment I) and a follow-up evaluation after completion of the 2-week program (Assessment II), at the same time of day, under the same conditions, and using the same measurement tools.

Eligibility criteria

Qualifiers

Diagnosed and clinically confirmed gait pattern asymmetry in the course of neurological diseases

Informed consent to participate in the study and willingness to comply with rehabilitation recommendations

Disqualifiers

Active rheumatic diseases, cancer, advanced diabetes, cardiovascular diseases, and other conditions that may affect the safety and effectiveness of rehabilitation

Contraindications to VR therapy (epilepsy, motion sickness, dizziness, nausea)

Lower limb injuries or surgeries within the last 6 months

Severe mental disorders preventing understanding of instructions

Trial design

Treatments tested in this trial

  • Virtual Reality (VR) and Standard Rehabilitation
  • Standard Rehabilitation

Treatment groups

40 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators